CARGO Therapeutics, Inc. Common Stock (CRGX)
USD 12.81
(-13.21%)
USD 12.81
(-13.21%)
| Breakdown | 2023 | 2022 | 2021 |
|---|---|---|---|
| Revenue | - | - | - |
| Cost of Revenue | 3.69 Million | 1.44 Million | 147 Thousand |
| Gross Profit | -3.69 Million | -1.44 Million | -147 Thousand |
| Operating Expenses | 96.71 Million | 34.77 Million | 5.97 Million |
| Selling, General and Administrative Expenses | 17.22 Million | 5.39 Million | 1.51 Million |
| Research and Development Expenses | 75.79 Million | 29.37 Million | 4.46 Million |
| Other Expenses | - | -22 Thousand | 127 Thousand |
| Cost and Expenses | 96.71 Million | 34.77 Million | 5.97 Million |
| Operating Income | -96.71 Million | -34.77 Million | -5.97 Million |
| Interest Expense | 1.6 Million | 4.94 Million | - |
| Income Tax Expense | - | 4.92 Million | 127 Thousand |
| Earnings before Tax | -98.14 Million | -40.95 Million | -5.85 Million |
| Net Income | -98.14 Million | -40.95 Million | -5.85 Million |
| Earnings Per Share Basic | -2.38 | -2.13 | -0.30 |
| Earnings Per Share Diluted | -2.38 | -2.13 | -0.30 |
| Weighted Average Shares Outstanding | 41.2 Million | 19.23 Million | 19.47 Million |
| Weighted Average Shares Outstanding (Diluted) | 41.2 Million | 19.23 Million | 19.47 Million |
| Gross Margin | - | - | - |
| EBIT Margin | - | - | - |
| Profit Margin | - | - | - |
| EBITDA | -93.01 Million | -33.34 Million | -5.7 Million |
| Earnings Before Tax Margin | - | - | - |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of Revenue | 2.06 Million | 1.85 Million | 3.69 Million | 1.1 Million | 1.08 Million | - |
| Gross Profit | -2.06 Million | -1.85 Million | -3.69 Million | -1.1 Million | -1.08 Million | - |
| Operating Expenses | 47.25 Million | 40.8 Million | 93.01 Million | 34.95 Million | 28.71 Million | 17.79 Million |
| Selling, General and Administrative Expenses | 10.39 Million | 10.3 Million | - | 7.88 Million | 6.47 Million | 3.86 Million |
| Research and Development Expenses | 36.85 Million | 30.5 Million | - | 27.06 Million | 22.23 Million | 13.92 Million |
| Other Expenses | -17 Thousand | -10 Thousand | - | 2.87 Million | -6.76 Million | 49 Thousand |
| Cost and Expenses | 49.31 Million | 40.8 Million | 96.71 Million | 34.95 Million | 28.71 Million | 17.79 Million |
| Operating Income | -49.31 Million | -40.8 Million | -96.71 Million | -34.95 Million | -28.71 Million | -17.79 Million |
| Interest Expense | - | - | 1.6 Million | - | - | - |
| Income Tax Expense | - | -10 Thousand | - | 2.87 Million | -6.76 Million | 49 Thousand |
| Earnings before Tax | -44.34 Million | -35.81 Million | -98.14 Million | -32.07 Million | -35.47 Million | -17.85 Million |
| Net Income | -44.34 Million | -35.81 Million | -98.14 Million | -32.07 Million | -35.47 Million | -17.85 Million |
| Earnings Per Share Basic | -1.02 | -0.87 | - | -0.78 | -0.92 | -0.46 |
| Earnings Per Share Diluted | -1.02 | -0.87 | - | -0.78 | -0.92 | -0.46 |
| Weighted Average Shares Outstanding | 43.34 Million | 41 Million | 41.2 Million | 41.21 Million | 38.67 Million | 38.67 Million |
| Weighted Average Shares Outstanding (Diluted) | 43.34 Million | 41 Million | 41.2 Million | 41.21 Million | 38.67 Million | 38.67 Million |
| Gross Margin | - | - | - | - | - | - |
| EBIT Margin | - | - | - | - | - | - |
| Profit Margin | - | - | - | - | - | - |
| EBITDA | -47.25 Million | -33.95 Million | - | -30.97 Million | -34.42 Million | -16.99 Million |
| Earnings Before Tax Margin | - | - | - | - | - | - |
HXL
SESN
ATMCW
300102
PTOS
CRVO